1 Introduction The global prevalence of non-alcoholic fatty liver disease (NAFLD) has shown a consistent upward trend in recent decades, with current estimates indicating an overall prevalence of 30.05% ( In a pivotal 2023 consensus statement, international liver associations proposed redefining disease terminology, replacing NAFLD with metabolic dysfunction-associated steatotic liver disease (MASLD) and NASH with metabolic dysfunction-associated steatohepatitis (MASH) ( MASLD pathogenesis involves complex interactions among multiple pathological processes, including excessive fatty acid accumulation, dysregulated inflammatory responses, oxidative stress, and insulin resistance
In a small prospective case series, published as an abstract only, diazoxide significantly improved late hypoglycaemia without having any statistically significant effects on other parameters 120
Rosenbaum, M., Murphy, E
during or within 14 days following administration of monoamine oxidase inhibitors
Tumor-specific peptides are a good choice to selectively target tumor-specific receptors
In September 2025, the FDA sent a letter to doctors warning of a potential connection between Tylenol use during pregnancy and the development of autism and ADHD
